Endoscopic sclerotherapy of oesophageal varices due to hepatosplenic schistosomiasis. A randomized controlled trial evaluating effect of sclerosant concentration.

Abstract

Forty consecutive patients with bleeding oesophageal varices underwent paravariceal injection with 2.5% or 5% ethanolamine oleate in a single-blind randomized controlled trial. Patients were injected on a weekly basis until varices were eradicated and then followed-up for a period of two years. Patients injected with 2.5% ethanolamine oleate experienced a significantly shorter duration of dysphagia and significantly less episodes of fever, ulceration, and luminal narrowing. Patients injected with 5% ethanolamine oleate required significantly less injection sessions to eradicate their varices. However, the probability of rebleeding was significantly lower in patients injected with 2.5% ethanolamine oleate. This study supports the use of ethanolamine in a concentration of 2.5% when injected paravariceally as it is associated with less complications and a lower probability of rebleeding.

• Authors: N Dowidar, A Hafez
• Journal: Journal of the Egyptian Society of Parasitology (J Egypt Soc Parasitol) Vol. 32 Issue 2 Pg. 537-49 (Aug 2002) ISSN: 1110-0583 [Print] Egypt
• PMID: 12214931 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Oleic Acids
• Sclerosing Solutions
• ethanolamine oleate

Topics

• Adult
• Aged
• Dose-Response Relationship, Drug
• Endoscopy
• Esophageal and Gastric Varices (etiology, therapy)
• Female
• Follow-Up Studies
• Gastrointestinal Hemorrhage (etiology, therapy)
• Humans
• Male
• Middle Aged
• Oleic Acids (administration & dosage)
• Recurrence
• Schistosomiasis (complications)
• Sclerosing Solutions (administration & dosage)
• Sclerotherapy (adverse effects)
• Single-Blind Method
• Treatment Outcome